Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline with first-line immunochemotherapy in advanced gastroesophageal adenocarcinoma
2022-001989-36Phase 2Active
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sertraline in esophagogastric junction cancer and gastroesophageal junction adenocarcinoma, sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoint: Objective response rate (best response CR or PR). Started Aug 2022; status: active.
02
Drugs
sertraline
03
Conditions
esophagogastric junction cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2022-001989-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001989-36.